Arya M et al. The metastatic cascade in prostate cancer. Surg Oncol 2006;[Epub ahead of print]. Abstract

Beekman K et al. Androgen deprivation for minimal metastatic disease: Threshold for achieving undetectable prostate-specific antigen. Urology 2005;65(5):947-52. Abstract

Beer TM et al. Multiple cycles of intermittent chemotherapy in metastatic androgen-independent prostate cancer. Br J Cancer 2004;91(8):1425-7. Abstract

Berthold DR, Moore MJ. Targeting metastatic prostate cancer: The search for innovative systemic therapies. Oncology (Williston Park) 2006;20(14):1787-91. Abstract

Burgess EF, Roth BJ. Changing perspectives of the role of chemotherapy in advanced prostate cancer. Urol Clin North Am 2006;33(2):227-36, vii. Abstract

Chodak GW. Maximum androgen blockade: A clinical update. Rev Urol 2005;7(Suppl 5):13-7. Abstract

Choueiri MB et al. The central role of osteoblasts in the metastasis of prostate cancer. Cancer Metastasis Rev 2006;25(4):601-9. Abstract

Collette L et al. Prostate-specific antigen (PSA) alone is not an appropriate surrogate marker of long-term therapeutic benefit in prostate cancer trials. Eur J Cancer 2006;42(10):1344-50. Abstract

Collette L et al; European Organisation for Research and Treatment of Cancer; Limburgs Universitair Centrum; AstraZeneca Pharmaceuticals. Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals. J Clin Oncol 2005;23(25):6139-48. Abstract

Dorff TB et al. Evolving treatment paradigms for locally advanced and metastatic prostate cancer. Expert Rev Anticancer Ther 2006;6(11):1639-51. Abstract

Doyle-Lindrud S. Implications of androgen-deprivation therapy in patients with prostate cancer: A case study. Clin J Oncol Nurs 2006;10(5):565-6. Abstract

Dreicer R. Chemotherapy for advanced prostate cancer: Docetaxel and beyond. Hematol Oncol Clin North Am 2006;20(4):935-46, x. Abstract

Drudge-Coates L. Skeletal complications and the use of bisphosphonates in metastatic prostate cancer. Int J Palliat Nurs 2006;12(10):462-9. Abstract

Eastham JA. Bone health in men receiving androgen deprivation therapy for prostate cancer. J Urol 2007;177(1):17-24. Abstract

Eisenberger MA, Sinibaldi VW. The role of cytotoxic chemotherapy in prostate cancer. A critical reevaluation 20 years later. Oncology (Williston Park) 2006;20(8):853-62. Abstract

Eisenberger MA et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998;339(15):1036-42. Abstract

Fleming MT et al. Post-therapy changes in PSA as an outcome measure in prostate cancer clinical trials. Nat Clin Pract Oncol 2006;3(12):658-67. Abstract

Halabi S et al. The impact of prior radical prostatectomy in men with metastatic castration recurrent prostate cancer: A pooled analysis of 9 Cancer and Leukemia Group B Trials. J Urol 2007;177(2):531-4. Abstract

Hurria A et al. Pharmacokinetics and toxicity of weekly docetaxel in older patients. Clin Cancer Res 2006;12(20 Pt 1):6100-5. Abstract

Hussain M et al; Southwest Oncology Group Trial 9346 (INT-0162). Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: Data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol 2006;24(24):3984-90. Abstract

Iversen P et al; Scandinavian Prostate Cancer Group. Bicalutamide 150 mg in addition to standard care for patients with early non-metastatic prostate cancer: Updated results from the Scandinavian Prostate Cancer Period Group-6 Study after a median follow-up period of 7.1 years. Scand J Urol Nephrol 2006;40(6):441-52. Abstract

Laber DA et al. A phase II study of higher dose docetaxel in androgen-independent prostate cancer. Am J Clin Oncol 2006;29(4):389-94. Abstract

Lin AM et al. Intermittent chemotherapy for metastatic hormone refractory prostate cancer. Crit Rev Oncol Hematol 2006;[Epub ahead of print]. Abstract

Loberg RD et al. A paradigm for the treatment of prostate cancer bone metastases based on an understanding of tumor cell-microenvironment interactions. J Cell Biochem 2005;96(3):439-46. Abstract

Loblaw DA et al; American Society of Clinical Oncology. American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. J Clin Oncol 2004;22(14):2927-41. Abstract

Lopez AM et al. Fracture risk in patients with prostate cancer on androgen deprivation therapy. Osteoporos Int 2005;16(6):707-11. Abstract

Lu-Yao G et al. Population based study of hormonal therapy and survival in men with metastatic prostate cancer. J Urol 2007;177(2):535-9. Abstract

Mannuel HD, Hussain A. Evolving role of surgery, radiation, hormone therapy, and chemotherapy in high-risk locally advanced prostate cancer. Clin Genitourin Cancer 2006;5(1):43-9. Abstract

Mike S et al. Chemotherapy for hormone-refractory prostate cancer. Cochrane Database Syst Rev 2006;(4):CD005247. Abstract

Oudard S et al. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer. J Clin Oncol 2005;23(15):3343-51. Abstract

Penson DF et al. The cost-effectiveness of combined androgen blockade with bicalutamide and luteinizing hormone releasing hormone agonist in men with metastatic prostate cancer. J Urol 2005;174(2):547-52. Abstract

Petrylak DP. The treatment of hormone-refractory prostate cancer: Docetaxel and beyond. Rev Urol 2006;8(Suppl 2):48-55. Abstract

Petrylak DP et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351(15):1513-20. Abstract

Petrylak DP. Docetaxel for the treatment of hormone-refractory prostate cancer. Rev Urol 2003;5(Suppl 2):14-21. Abstract

Saad F. Bone-directed treatments for prostate cancer. Hematol Oncol Clin North Am 2006;20(4):947-63. Abstract

Saad F et al. Canadian Urologic Oncology Group (CUOG) phase II study using docetaxel/prednisone in the second line setting for metastatic androgen independent prostate cancer in patients progressing after first line mitoxantrone/prednisone. Proc AUA 2006;Abstract 1199.

Semeniuk RC et al. Prostate-specific antigen doubling time is associated with survival in men with hormone-refractory prostate cancer. Urology 2006;68(3):565-9. Abstract

Southwest Oncology Group. Quality of life and pain in advanced stage prostate cancer: Results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone. J Clin Oncol 2006;24(18):2828-35. Abstract

Tan WW. Novel agents and targets in managing patients with metastatic prostate cancer. Cancer Control 2006;13(3):194-8. Abstract

Tannock IF et al; TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351(15):1502-12. Abstract

Tester W et al. Phase I/II study of weekly docetaxel and vinblastine in the treatment of metastatic hormone-refractory prostate carcinoma. Cancer J 2006;12(4):299-304. Abstract

Tyrrell CJ et al. Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration. BJU Int 2006;98(3):563-72. Abstract

Walsh PC. American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. J Urol 2005;173(6):1966. No abstract available

Wirth M et al. Bicalutamide (Casodex) 150 mg plus standard care in early non-metastatic prostate cancer: Results from Early Prostate Cancer Trial 24 at a median 7 years’ follow-up. Prostate Cancer Prostatic Dis 2006;[Epub ahead of print]. Abstract

Youssef E et al. Intermittent androgen deprivation for patients with recurrent/metastatic prostate cancer. Am J Clin Oncol 2003;26(5):e119-23. Abstract

Yoshida T et al. Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient. Cancer Res 2005;65(21):9611-6. Abstract